This review summarizes the clinical manifestations and pharmacological management strategies, including beta-blockers, ARBs, and statins, for children and adolescents with Marfan syndrome.
Answers are grounded in this paper and cite their sources.
Does not alter practice in pediatric Marfan syndrome; leaves open need for pediatric RCTs on beta-blockers, ARBs, and statins.
Marfan syndrome is a hereditary, autosomal disease with a relatively high prevalence in the general population. Numerous manifestations of Marfan syndrome are expressed in a wide range of disorders involving cardiovascular, ocular and musculoskeletal systems. The article describes the principles of management of the syndrome in children and adolescents. Clinical manifestations of the disease are evaluated in young patients of different age groups. There are presented data on the main medicines used in the therapy of Marfan syndrome, such as beta-blockers, angiotensin receptor blockers, statins. Relevant literature was searched using the databases PubMed, MedLine, Scopus, Web of Science. The article will be interesting to a wide range of specialists: pediatricians, cardiologists, general practitioners and other specialties
No takes yet. Share an insight, caveat, or question.
Лунева et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: